WO2021207051A1 - Méthodes de traitement de troubles respiratoires aigus - Google Patents

Méthodes de traitement de troubles respiratoires aigus Download PDF

Info

Publication number
WO2021207051A1
WO2021207051A1 PCT/US2021/025725 US2021025725W WO2021207051A1 WO 2021207051 A1 WO2021207051 A1 WO 2021207051A1 US 2021025725 W US2021025725 W US 2021025725W WO 2021207051 A1 WO2021207051 A1 WO 2021207051A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
patient
covid
effective amount
pharmaceutically acceptable
Prior art date
Application number
PCT/US2021/025725
Other languages
English (en)
Inventor
Michael Antonio MALDONADO
Subhashis Banerjee
Sheila Marie Kelly
Brian James GAVIN
Sean Eugene CONNOLLY
Liyanage Vidya PERERA
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of WO2021207051A1 publication Critical patent/WO2021207051A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne des méthodes de traitement d'un trouble respiratoire.
PCT/US2021/025725 2020-04-06 2021-04-05 Méthodes de traitement de troubles respiratoires aigus WO2021207051A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063006052P 2020-04-06 2020-04-06
US63/006,052 2020-04-06
US202063050409P 2020-07-10 2020-07-10
US63/050,409 2020-07-10

Publications (1)

Publication Number Publication Date
WO2021207051A1 true WO2021207051A1 (fr) 2021-10-14

Family

ID=78023600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025725 WO2021207051A1 (fr) 2020-04-06 2021-04-05 Méthodes de traitement de troubles respiratoires aigus

Country Status (1)

Country Link
WO (1) WO2021207051A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2781235C1 (ru) * 2022-05-30 2022-10-07 Общество С Ограниченной Ответственностью "Импульс Жизни" Способ определения наличия реакции Т-клеток в крови человека на присутствие антигенов SARS-CoV2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8454938B2 (en) * 2005-12-21 2013-06-04 Solaeromed Inc. Treatment of respiratory diseases
US20170165236A1 (en) * 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
US20190084947A1 (en) * 2008-05-14 2019-03-21 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
US20190381041A1 (en) * 2010-11-07 2019-12-19 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8454938B2 (en) * 2005-12-21 2013-06-04 Solaeromed Inc. Treatment of respiratory diseases
US20190084947A1 (en) * 2008-05-14 2019-03-21 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
US20190381041A1 (en) * 2010-11-07 2019-12-19 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
US20170165236A1 (en) * 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. WU ET AL.: "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China", JAMA INTERN MED, vol. 180, no. 7, 2020, pages 934 - 943, XP055804183, DOI: 10.1001/jamainternmed.2020.0994 *
DATABASE PubChem 3 September 2007 (2007-09-03), XP055866316, Database accession no. 16722836 *
FERNANDEZ-DIAZ ET AL.: "ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE: A NATIONAL MULTICENTER STUDY OF 63 PATIENTS", SEMINARS IN ARTHRITIS AND RHEUMATISM, vol. 48, no. 1, 2018, pages 22 - 27, XP085442433, DOI: 10.1016/j.semarthrit.2017.12.012 *
WALSH ET AL.: "Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus", PNAS, vol. 108, no. 29, 2011, pages 12018 - 12023, XP055866315 *
WU ET AL.: "TH 17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib", JOURNAL OF MICROBIOLOGY, IMMUNOLOGY AND INFECTION, vol. 53, March 2020 (2020-03-01), pages 368 - 370, XP086170990, DOI: 10.1016/j.jmii.2020.03.005 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2781235C1 (ru) * 2022-05-30 2022-10-07 Общество С Ограниченной Ответственностью "Импульс Жизни" Способ определения наличия реакции Т-клеток в крови человека на присутствие антигенов SARS-CoV2

Similar Documents

Publication Publication Date Title
Zhang et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
CN115605508A (zh) 用于治疗冠状病毒感染和所产生的炎症诱导的肺损伤的方法
US11364227B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
KR20230005957A (ko) Covid-19 치료 방법
WO2021207051A1 (fr) Méthodes de traitement de troubles respiratoires aigus
TW202320778A (zh) 新型冠狀病毒感染症治療劑
CN115867577A (zh) 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
WO2021203013A2 (fr) Méthodes de traitement d'une lésion pulmonaire à médiation immunitaire
WO2021163400A1 (fr) Compositions et méthodes de traitement d'infections à coronavirus
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
JP2023541921A (ja) Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
US20230285510A1 (en) Treatment of coronavirus infection with interferon lambda
US20230151107A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
US20240025991A1 (en) Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
TW202245799A (zh) 治療冠狀病毒感染及由其導致之發炎所誘發的肺損傷之方法
JP2023520216A (ja) 過剰な遊離ｌｉｇｈｔに関与する方法及び治療
KR20220010456A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
WO2024038186A1 (fr) Traitement d'une insuffisance respiratoire aiguë
KR20220010410A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
CA3230303A1 (fr) Echafaudages derives de tn3 specifiques a cd40l destines a etre utilises dans le traitement et la prevention de la polyarthrite rhumatoide
Kaur et al. An Update on Management of Severe COVID19 Presenting with Cytokine Release Syndrome Responsible for Most Mortalities in COVID19
WO2021194860A1 (fr) Polythérapie à base de tocilizumab et de remdesivir pour une pneumonie à covid-19
KR20220010411A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
CN116490520A (zh) 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21785212

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21785212

Country of ref document: EP

Kind code of ref document: A1